Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics
Renovaro (NASDAQ: RENB) has entered into an exclusive collaboration agreement with Amsterdam University Medical Center to develop and evaluate blood platelet RNA diagnostics. The partnership aims to advance disease detection and monitoring by leveraging Renovaro's AI/Machine Learning capabilities and Nebul's compute resources to analyze disease-specific signals from blood samples.
The four-year collaboration will focus on improving predictive performance and clinical accuracy across multiple cancer types through blood sample analysis, data integration, and deep learning model development. Both organizations will jointly manage intellectual property and plan to establish a dedicated company in the Netherlands for commercialization purposes.
Renovaro (NASDAQ: RENB) ha stipulato un accordo di collaborazione esclusiva con il Centro Medico Universitario di Amsterdam per sviluppare e valutare diagnostica basata sull'RNA delle piastrine del sangue. La partnership mira a migliorare la rilevazione e il monitoraggio delle malattie sfruttando le capacità di intelligenza artificiale e apprendimento automatico di Renovaro e le risorse di calcolo di Nebul per analizzare segnali specifici delle malattie nei campioni di sangue.
La collaborazione quadriennale si concentrerà sul miglioramento delle prestazioni predittive e dell'accuratezza clinica in diversi tipi di cancro, attraverso l'analisi dei campioni di sangue, l'integrazione dei dati e lo sviluppo di modelli di deep learning. Entrambe le organizzazioni gestiranno congiuntamente la proprietà intellettuale e prevedono di costituire una società dedicata nei Paesi Bassi a scopo commerciale.
Renovaro (NASDAQ: RENB) ha establecido un acuerdo de colaboración exclusivo con el Centro Médico Universitario de Ámsterdam para desarrollar y evaluar diagnósticos basados en ARN de plaquetas sanguíneas. La asociación busca avanzar en la detección y el monitoreo de enfermedades aprovechando las capacidades de inteligencia artificial y aprendizaje automático de Renovaro y los recursos computacionales de Nebul para analizar señales específicas de enfermedades en muestras de sangre.
La colaboración de cuatro años se centrará en mejorar el rendimiento predictivo y la precisión clínica en varios tipos de cáncer mediante el análisis de muestras de sangre, la integración de datos y el desarrollo de modelos de aprendizaje profundo. Ambas organizaciones gestionarán conjuntamente la propiedad intelectual y planean establecer una empresa dedicada en los Países Bajos con fines comerciales.
Renovaro (NASDAQ: RENB)는 암스테르담 대학 의료 센터와 독점 협력 계약을 체결하여 혈소판 RNA 진단법을 개발하고 평가할 예정입니다. 이 파트너십은 Renovaro의 AI/머신러닝 역량과 Nebul의 컴퓨팅 자원을 활용하여 혈액 샘플에서 질병 특이 신호를 분석함으로써 질병 탐지 및 모니터링을 발전시키는 것을 목표로 합니다.
4년간 진행되는 이번 협력은 혈액 샘플 분석, 데이터 통합, 딥러닝 모델 개발을 통해 여러 암 유형에서 예측 성능과 임상 정확도를 향상시키는 데 중점을 둘 것입니다. 양 기관은 지적 재산권을 공동 관리하며 상업화를 위해 네덜란드에 전담 회사를 설립할 계획입니다.
Renovaro (NASDAQ : RENB) a conclu un accord de collaboration exclusif avec le Centre médical universitaire d'Amsterdam pour développer et évaluer des diagnostics basés sur l'ARN des plaquettes sanguines. Ce partenariat vise à améliorer la détection et le suivi des maladies en exploitant les capacités d'intelligence artificielle et d'apprentissage automatique de Renovaro ainsi que les ressources informatiques de Nebul pour analyser les signaux spécifiques aux maladies à partir d'échantillons sanguins.
La collaboration, d'une durée de quatre ans, se concentrera sur l'amélioration des performances prédictives et de la précision clinique pour plusieurs types de cancers grâce à l'analyse des échantillons sanguins, l'intégration des données et le développement de modèles d'apprentissage profond. Les deux organisations géreront conjointement la propriété intellectuelle et prévoient de créer une société dédiée aux Pays-Bas à des fins commerciales.
Renovaro (NASDAQ: RENB) hat eine exklusive Kooperationsvereinbarung mit dem Amsterdam University Medical Center geschlossen, um RNA-Diagnostik von Blutplättchen zu entwickeln und zu evaluieren. Die Partnerschaft zielt darauf ab, die Krankheitsdetektion und -überwachung voranzutreiben, indem Renovaros KI/Maschinelles Lernen Fähigkeiten und Nebuls Rechenressourcen genutzt werden, um krankheitsspezifische Signale aus Blutproben zu analysieren.
Die vierjährige Zusammenarbeit wird sich darauf konzentrieren, die prognostische Leistung und klinische Genauigkeit bei verschiedenen Krebsarten durch Blutprobenanalyse, Datenintegration und Entwicklung von Deep-Learning-Modellen zu verbessern. Beide Organisationen werden das geistige Eigentum gemeinsam verwalten und planen, ein dediziertes Unternehmen in den Niederlanden für kommerzielle Zwecke zu gründen.
- Strategic partnership with a leading medical research institution
- Access to advanced blood platelet RNA diagnostic technology
- Joint intellectual property management and commercialization rights
- Planned establishment of a dedicated company for product development
- Long development timeline with initial four-year term
- No immediate revenue generation potential
- Success dependent on clinical validation outcomes
Insights
Renovaro's exclusive partnership with Amsterdam UMC accelerates development of innovative RNA-based cancer diagnostics with commercial potential.
Renovaro's new partnership with Amsterdam UMC represents a strategic move into the emerging field of blood platelet RNA diagnostics, which could potentially transform cancer detection and monitoring. The collaboration leverages Renovaro's AI/ML capabilities and their recently announced compute resources from Nebul to analyze disease-specific RNA signatures in blood platelets.
What makes this partnership particularly valuable is the exclusive nature of the collaboration, giving Renovaro privileged access to Amsterdam UMC's clinical expertise and research capabilities. The four-year term provides sufficient runway to develop meaningful clinical validation, while the explicit mention of commercialization plans through a dedicated Netherlands-based company demonstrates a clear path to market.
From a technological perspective, platelet RNA represents an innovative biomarker source that hasn't yet been widely commercialized. Platelets (which lack a nucleus) can absorb RNA from tumors and other diseased cells, potentially offering a unique "liquid biopsy" approach that may complement or compete with existing ctDNA technologies. The emphasis on multiple cancer types suggests broad applications if successful.
However, investors should recognize this collaboration remains in the research and development phase. The press release doesn't mention specific timelines for clinical validation milestones, regulatory submissions, or commercialization targets. The focus on "refining and improving predictive performance" indicates the technology likely needs further optimization before clinical deployment.
This partnership aligns with Renovaro's broader strategy positioning itself as a "TechBio leader" combining biological insights with computational methods. The joint IP management structure suggests equitable value sharing between the partners, though specific economic terms weren't disclosed.
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center (“Amsterdam UMC”) to jointly evaluate and develop blood platelet RNA diagnostics. This partnership marks an important step forward in the clinical validation and advancement of a promising new approach to disease detection and monitoring.
The collaboration will focus on assessing the clinical utility of blood platelet RNA signatures as a powerful biomarker source. This effort will leverage the unique Artificial Intelligence (“AI”)/Machine Learning (“ML”) capabilities of Renovaro as well as the newly announced compute resources provided through their agreement with Nebul, to uncover subtle disease-specific signals from blood samples and is aimed at transforming diagnostic and prognostic approaches across multiple cancer types.
Under the terms of the agreement, Renovaro and Amsterdam UMC will work together to refine and improve predictive performance, aiming for a high degree of clinical accuracy. The project will involve collection and analysis of blood samples, data integration from multiple modalities, and the development of sophisticated deep learning models.
“We are excited to partner with Amsterdam UMC, a leader in translational research, to advance this promising technology,” said David Weinstein, CEO of Renovaro. “By combining their clinical expertise with our technological capabilities, we believe we can significantly accelerate the translation of blood platelet RNA diagnostics into clinical practice.”
Both organizations have committed to jointly manage the intellectual property arising from the collaboration and plan to establish a dedicated company in the Netherlands to further develop and commercialize resulting diagnostics.
The initial term of the collaboration is four years, with the possibility of extension by mutual agreement.
About Amsterdam UMC
Amsterdam UMC is a leading medical center that combines complex high-quality patient care, innovative scientific research, and education of the next generation health care professionals. We believe that health care practice, research and education belong together, with each shaping and informing the other. With over 16,000 people, the two locations of Amsterdam UMC work together to provide good and accessible care. Amsterdam UMC is focused on a future where diseases can be prevented and where patients receive the best treatments. The emphasis is on the complex treatment of rare disorders.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development, and BioSymetrics which specializes in contingent AI for precision neurology. For more information, visit www.renovarogroup.com.
Forward-Looking Statements
This press release contains statements by Renovaro Biosciences Inc. (“Renovaro”, “we”, “us”, “our” or the “Company”) that are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, our prospects, plans, business strategy and expected financial and operational results. You can identify these statements by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would”, ”could”, ”project”, ”plan”, “potential”, ”designed”, “seek”, “target”, variations of these terms, the negatives of such terms and similar expressions. These statements are based on certain assumptions that we have made in light of our experience in our industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. You should not rely on forward-looking statements because our actual results may differ materially from those indicated by forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: the success or efficacy of our pipeline, platform and fundraising; our ability to successfully integrate business that we have acquired, including BioSymetrics, or that we may acquire; our ability to achieve the benefits that we expect to realize as a result of our acquisitions, including BioSymetrics; and those other risks and uncertainties discussed in the reports we have filed with the Securities and Exchange Commission (the “SEC”), such as our most recent Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date the statements were made. We do not undertake any obligation to update forward-looking information, except to the extent required by applicable law.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
FAQ
What is the purpose of Renovaro's (RENB) collaboration with Amsterdam UMC?
How long is the collaboration agreement between Renovaro (RENB) and Amsterdam UMC?
What technology will Renovaro (RENB) use in this collaboration?
How will the intellectual property be managed in the Renovaro-Amsterdam UMC partnership?
What is the potential impact of Renovaro's (RENB) blood platelet RNA diagnostics?
